Connect Biopharma is trading 10.51% down at $2.47 after two consecutive strong sessions, including a 16.95% gain on September 2; no new company-specific announcement explaining the September 3 decline was identified.
- Investors remain focused on anticipated September topline results from the Seabreeze STAT asthma and COPD studies.
- Broader biotechnology strength has not prevented today’s pullback.